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Prostate cancer (PCa) is the most common malignancy affecting men in the western world. 30 
While radical prostatectomy and radiation therapy can successfully treat a majority of patients, 31 
up to ~30% will experience local recurrence or metastatic disease. Prostate carcinogenesis and 32 
progression is typically an androgen dependent process. For this reason, therapies for recurrent 33 
PCa target androgen biosynthesis and androgen receptor function. Whilst such androgen 34 
deprivation therapies (ADT) are effective initially, the duration of response is typically ≤24 35 
months. While ADT and taxane based chemotherapy have delivered survival benefits, 36 
metastatic prostate cancer remains incurable. Therefore it is essential to establish the cellular 37 
and molecular mechanisms which enable localized prostate cancers to invade and disseminate. 38 
It has long been accepted that metastases requires angiogenesis. In this review we will examine 39 
the essential role for angiogenesis in PCa metastases and in particular we will focus on current 40 
understanding of the regulation of vascular endothelial growth factor (VEGF) in localized and 41 
metastatic PCa. We will highlight recent advances in understanding the role of VEGF in 42 
regulating interaction of cancer cells with tumor7associated immune cells during metastatic 43 
process of PCa.  We will summarize the established mechanisms of transcriptional and post744 
transcriptional regulation of VEGF in prostate cancer cells and will outline the molecular insights 45 
obtained from pre7clinical animal models of prostate cancer. Finally we will summarize the 46 
current state of anti7angiogenesis therapies for PCa and how existing therapies impact on 47 
VEGF signalling.  48 
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Prostate cancer (PCa) is the most common malignancy affecting western men (Ferlay, et al. 50 
2013; Siegel, et al. 2015) and is estimated to account for over 220,000 new cases and 27,000 51 
deaths in the United States in 2015. Advances in early diagnosis (Carter, et al. 2013; 52 
Heidenreich, et al. 2013), surgical, radio7, chemo7 and immuno7 therapies (reviewed in Lorente 53 
and De Bono 2014; Stewart and Boorjian 2014), are improving patient survival. However, the 54 
aging demographics of western countries suggest PCa will remain a leading cause of cancer 55 
related mortality in men. Although >90% of PCa are diagnosed as androgen responsive acinar 56 
adenocarcinoma (Humphrey 2012), the disease is clinically heterogeneous. Indeed it is 57 
currently not possible to accurately distinguish high risk prostate tumors, which require 58 
extensive therapeutic intervention, from patients with low risk indolent tumors, many of which 59 
would not require any therapy (Cuzick, et al. 2014; Draisma, et al. 2009; Tombal, et al. 2014; 60 
Weiner, et al. 2015). Therefore most men with clinically localized PCa undergo radical 61 
prostatectomy or radiotherapy with curative intent (Boorjian, et al. 2012; Heidenreich, et al. 62 
2014). Yet, it has been estimated that between 20730% of cases will experience recurrence 63 
(Boorjian et al. 2012). Following local recurrence and metastasis, androgen deprivation therapy, 64 
achieved medically or through orchiectomy, is typically effective for <24 months by which time 65 
progression to the more detrimental form of castrate resistant PCa (CRPC) is common (Ahmed, 66 
et al. 2014). PCa becomes hormone refractory and cancer cells acquire the ability to invade and 67 
metastasize to lymph nodes and distant organs (Wegiel, et al. 2005).  68 
The importance of androgen signalling in prostate carcinogenesis has long been 69 
recognized (Huggins and Hodges 1941). In the intervening decades it became apparent that 70 
androgen signalling plays essential roles in localized and metastatic PCa (Wang, et al. 2009). 71 
The androgen receptor (AR) is a member of the ligand dependent transcription factor family of 72 
nuclear receptors which also includes the estrogen (ERα/ERβ) and progesterone (PR) 73 
receptors, lipophilic ligands (retinoids, vitamin D) and orphan receptors for which ligands have 74 
not been identified. In the presence of an agonist, nuclear receptors regulate gene expression 75 
by recruiting epigenetic coregulator proteins with histone lysine acetyltransferase (KAT), 76 
methyltransferase (KMT) and demethylase (KDM) activity. Consistent with the essential role 77 
played by androgens and the AR in hormone dependent (Yu, et al. 2010) and refractory PCa 78 
(Wang et al. 2009), nuclear receptor coregulators have also been implicated in prostate 79 
carcinogenesis and progression (Debes, et al. 2003; Heemers, et al. 2007; Rahman, et al. 80 
2003). KDMs are key coregulators of AR and ER transcriptional activation and repression 81 
(Cheng and Blumenthal 2010; Kooistra and Helin 2012). A subset of KDMs, including 82 
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KDM1A/LSD1, are over7expressed in PCa (Kahl, et al. 2006; Kashyap, et al. 2013; Metzger, et 83 
al. 2005). Although KDM1A acts predominantly as a transcriptional corepressor, KDM1A can act 84 
as a coactivator for AR (Metzger et al. 2005) and ERα (Perillo, et al. 2008) dependent upon 85 
promoter context (Cai, et al. 2011). Consistent with this there is evidence that KDM1A can 86 
contribute to hormone refractory PCa by sensitizing prostate cells to lower androgen levels (Cai 87 
et al. 2011; Cai, et al. 2014). Androgen and estrogen receptors are known to cooperate in gene 88 
regulation in PCa and can define transcriptional signatures associated with aggressive disease 89 
(Setlur, et al. 2008). As we will discuss in detail later, KDM1A appears to promote PCa 90 
recurrence in part by enhancing androgen7regulated VEGF expression (Kashyap et al. 2013). 91 
With a clear clinical need for new treatments, nuclear receptor epigenetic coregulators and 92 
related proteins are attractive therapeutic targets, due to their feasibility as ‘druggable’ targets 93 
(Asangani, et al. 2014; Dawson and Kouzarides 2012; Rotili, et al. 2014). For this reason 94 
recently identified coregulator components of the AR7signaling complex represent potential new 95 
targets to circumvent resistance to existing therapies.  96 
Androgen deprivation therapies (ADT) are the standard treatment for locally advanced 97 
and metastatic PCa. ADT targets androgen receptor (AR) signaling pathways which are central 98 
to gene expression programs driving prostate tumour growth and metastasis. AR signaling 99 
persists in hormone refractory PCas which are resistant to ADT (Wang et al. 2009). Although 100 
androgen deprivation therapies impede tumor progression, hormone refractory cancers bypass 101 
androgen dependency and remain incurable. Recently introduced CRPC therapies include 102 
abiraterone, an inhibitor of a key enzyme in androgen biosynthesis, and the potent AR 103 
antagonist, enzalutamide. While both abiraterone and enzalutamide have demonstrated survival 104 
benefits in the CRPC context, the duration of response to these agents remains disappointing 105 
(de Bono, et al. 2011; Scher, et al. 2012). Furthermore, one consequence of prolonged systemic 106 
androgen blockade is the increasing emergence of neuroendocrine PCa which is associated 107 
with aggressive disease and poor prognosis (Beltran, et al. 2011). Whilst we now have 108 
unparalleled insight into the genomic complexity of PCa (Baca, et al. 2013; Barbieri, et al. 2012; 109 
Barbieri, et al. 2013; Berger, et al. 2011), there is therefore an urgent need to exploit this 110 
knowledge with a view to identifying novel approaches to prevent or delay PCa metastases.  111 
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Pro7angiogenic pathways are essential mediators of tumor growth and metastasis, and as a 114 
consequence the potential for therapies targeting the tumor vasculature has long been 115 
recognized (Folkman 1971; Folkman, et al. 1971). Both normal and pathologic angiogenesis is 116 
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regulated predominantly by the vascular endothelial growth factors (VEGF7A, 7B, 7C and 7D) and 117 
their cognate cell surface receptors (VEGFR1, VEGFR2, VEGFR3) which can also be activated 118 
by neuropilins (Roskoski 2007). VEGF isoforms exhibit distinct receptor affinities and activate 119 
the intra7cellular receptor tyrosine kinase signalling cascade. The VEGFs and their receptors 120 
also play a role in PCa lymphangiogenesis (Burton, et al. 2008; Wong, et al. 2005). In this 121 
review we will focus on the regulation and function of VEGFA (also referred to as simply VEGF) 122 
in angiogenesis. VEGF is over7expressed in a variety of haematological malignancies 123 
(Krejsgaard, et al. 2006) and the vast majority of solid tumors including PCa (Wegiel et al. 124 
2005)(Figure 1) where it is associated with poorer outcomes (Duque, et al. 1999; Green, et al. 125 
2007). In prostate, in addition to its expression in blood and lymphatic endothelial cells, VEGF is 126 
also expressed at low levels in prostatic glandular epithelial cells and in nonvascular cells such 127 
as macrophages, fibroblast and mast cells (Hrouda, et al. 2003). Chronic prostatic inflammation 128 
and the infiltration of macrophages and other immune cells that express high level of VEGF is 129 
believed to be an important event during the malignant transformation. The increased 130 
production of cytokines such as interleukin76 is believed to induce VEGF expression in the 131 
infiltrating immune cells (Cohen, et al. 1996). It has been shown that bacterial 132 
lipopolysaccharide (LPS) induces the expression of Toll7like receptors (TLRs) in human prostate 133 
epithelial PC3 cells after exposure to bacterial infection. This increased expression of TLRs is 134 
able to induce VEGF expression which in turn triggers the proliferation and migratory ability of 135 
PCa cells (Pei, et al. 2008). 136 
The V promoter is regulated by a multiple transcription factor complexes and the 137 
function of the hypoxia7inducible factors (HIFs) in the regulation of  expression is well 138 
understood (Forsythe, et al. 1996; Gray, et al. 2005). However over the last decade it has 139 
become apparent that the promoter can be regulated by multiple members of the nuclear 140 
receptor family, including the AR (Eisermann, et al. 2013), estrogen (ERα/cMyc) (Buteau7141 
Lozano, et al. 2002; Dadiani, et al. 2009), progesterone (Wu, et al. 2004), vitamin D (Cardus, et 142 
al. 2009) and the liver7X receptors (LXR) (Walczak, et al. 2004). Consistent with this, animal 143 
studies have indicated a role for androgens and estrogen in prostate vascularization (Daehlin, et 144 
al. 1985). In this context it is interesting to note that nuclear receptor7coregulator complexes can 145 
regulate splicing events (Auboeuf, et al. 2004; Auboeuf, et al. 2002). Thus a role for aberrant 146 
recruitment of nuclear receptor7complexes to the  promoter in the induction of pro7147 
angiogenic VEGF splicing during carcinogenesis cannot be excluded (Figure 2).  148 
Interestingly, pro7 and anti7angiogenic VEGF splice forms have been identified (Bates et 149 
al 2002), which are differentially regulated in cancers, including in PCa (Mavrou, et al. 2014; 150 
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Woolard, et al. 2004) and which may be key to the development of future therapies targeting 151 
pro7angiogenic VEGF function (Harper and Bates 2008). In the terminal exon of the vegf gene 152 
(Exon 8) there are two potential splice sites. A proximal splice site (PSS) encodes 6 amino acids 153 
(CDKPRR) before a stop codon is reached, resulting in isoforms such as VEGF7A165a. The use 154 
of the PSS results in generation of angiogenic isoforms that increase vascular permeability, 155 
stimulate vessel growth and result in vasodilatation. Further into the terminal exon, a distal 156 
splice site (DSS), 66 bases downstream of the PSS, results in an alternative open reading 157 
frame of the same size (6 amino acids, SLRTKD), resulting in a different C7terminus to the 158 
protein. And VEGF7A165b This switches the protein to an anti7angiogenic one that can inhibit 159 
vasodilatation (Woolard et al. 2004), and reduce permeability (Oltean, et al. 2012). The splice 160 
variants are differentially regulated (e.g. SRPK1 stimulates splicing to VEGF7A165a, and Clk1/4 161 
to VEGF7A165b) (Nowak, et al. 2010; Nowak, et al. 2008) and are differentially reguated post7162 
transcriptionally – e.g. by T7cell intracellular Antigen 1, an RNA binding protein that differentially 163 
regulates translation and splicing of VEGF through activation by ras (Hamdollah Zadeh, et al. 164 
2015).  165 
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Regulation of VEGF expression can occur at multiple points between transcription and 168 
translation, these regulatory effects broadly fall into three different areas; pre7mRNA processing 169 
(alternative splicing as discussed above), mRNA transcript stability and control of translation. 170 
The latter two categories will be discussed in this section, with a focus on the mechanisms of 171 
VEGF post7transcriptional regulation in PCa.  172 
Variations in mRNA transcript stability are commonly seen as a cellular7response to 173 
environmental changes such as stress and nutrient availability, acting as a rapid response to 174 
maintain protein homeostasis.  is tightly regulated at the transcript level and whilst the 175 
reported half7life is short, 15740 minutes  	
, this can be substantially extended during 176 
periods of hypoxia and nutrient withdrawal (Dibbens, et al. 1999; Ikeda, et al. 1995; Levy, et al. 177 
1996; Shima, et al. 1995). AU7rich elements (ARE) within the 3’UTR of the VEGF transcript 178 
along with other elements within the coding and untranslated regions are potential targets for a 179 
range of RNA binding proteins, resulting in both positive and negative effects on transcript 180 
stability (Chang, et al. 2013; Claffey, et al. 1998; Coles, et al. 2004; Fellows, et al. 2012; 181 
Goldberg7Cohen, et al. 2002; King 2000; Onesto, et al. 2004; Shih and Claffey 1999). Hypoxia7182 
dependent regulation of transcript stability has been well characterised in a number of cancer 183 
types and recently reviewed in (Arcondeguy, et al. 2013). 184 
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Interestingly, two less well characterised methods of hypoxia7independent regulation of 185 
VEGF transcript stability have been observed in studies of PCa. The first occurring when DU145 186 
PCa cells were subjected to glucose deprivation. Under these conditions, VEGF transcript 187 
stability was increased as a result of the stimulation of AMP7activated Protein Kinase (AMPK), 188 
through an as yet unknown mechanism (Yun, et al. 2005). Further to this, an isoform of the 189 
Wilm’s Tumour Suppressor Gene (WT17A) was found to modestly increase VEGF transcript 190 
stability in a hormone enhanced mechanism, when WT1 was stably over7expressed in LNCaP 191 
PCa cells. Over7expression of other WT1 isoforms lacking the third of four zinc finger domains 192 
were unable to mediate VEGF stability, indicating the potential importance of zinc finger 193 
domains in this regulatory mechanism (Cash, et al. 2007). 194 
Eukaryotic protein translation predominantly depends on the m7G cap structure of the 195 
mRNA and assembly of the translation initiation complex (cap7dependent translation). However, 196 
alternative mechanisms of cap7independent translation have evolved, in order to maintain or 197 
activate the translation of essential proteins during periods of cellular7stress when cap7198 
dependent translation is impaired (reviewed (Van Der Kelen, et al. 2009)). Cap7independent 199 
mechanisms depend upon the presence of Internal Ribosome Entry Sites (IRES) to enable 200 
initiation of translation, whilst originally identified in viruses, multiple eukaryotic mRNAs including 201 
VEGF are reported to contain IRES sequences (Jang, et al. 1988; Pelletier and Sonenberg 202 
1988). The VEGF mRNA 5’UTR features two IRESs; IRES7A and IRES7B 293 and 947 203 
nucleotides upstream of the canonical AUG start site respectively, the position of IRES7B is also 204 
just over 40 nucleotides upstream of an alternative CUG start codon (Akiri, et al. 1998; Huez, et 205 
al. 1998; Miller, et al. 1998). A single7nucleotide polymorphism (SNP) of the VEGF gene (7634 206 
C>G substitution) has been linked with increased risk of PCa (Sfar, et al. 2006). This SNP was 207 
found to impair IRES7B function, reducing translation initiated from the alternative CUG start 208 
codon (Lambrechts, et al. 2003). Furthermore, a 17 nucleotide sequence within VEGF IRES7A 209 
has been shown to promote the formation of an intramolecular G7quadruplex structure (Morris, 210 
et al. 2010). G7quadruplex formation potentially regulates multiple aspects of RNA regulation, in 211 
the case of VEGF, mutations of this 17 nucleotide sequence prevents G7quadruplex formation 212 
and results in inhibition of IRES7A function (Morris et al. 2010). The contribution of G7quadruplex 213 
regulation to VEGF expression in PCa remains to be determined, but given the role of IRESs in 214 
mediating VEGF translation under stress conditions these intramolecular structures warrant 215 
further investigation.  216 
Translation efficiency of VEGF can be further modified by microRNAs (miRNAs), a class 217 
of small non7coding RNA. MicroRNAs regulate translation by binding to specific sequences 218 
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within the target mRNA, usually these binding sites reside within the 3’UTR but can also occur 219 
in the 5’UTR and coding regions (Tay, et al. 2008). Target binding is mediated by the miRNA7220 
associate RNA Induced Silencing Complex (mi7RISC) and results in either the repression of 221 
translation or mRNA degradation, with the net result of both processes being reduced protein 222 
expression (reviewed in (Huntzinger and Izaurralde 2011)). Analysis of prostate tissue and cell 223 
lines have identified multiple miRNAs, the expression of which are consistently altered in 224 
prostate tumors, leading to further analysis of downstream gene targets and their potential 225 
contribution to carcinogenesis. Szczyrba 	 . reported a significant reduction of miR729b 226 
expression in PCa and subsequently demonstrated miR729b as a direct regulator of VEGF in 227 
PCa cell lines LNCaP and DU145 (Szczyrba, et al. 2010; Szczyrba, et al. 2013).   228 
In addition to miR729b, the VEGF transcript is predicted to contain binding sites for 229 
multiple miRNA types (as highlighted in Figure 2C), such as miR7145 and miR7205, the 230 
expression of which are reduced in PCa and have been shown to regulate VEGF in other 231 
cancer types (Boll, et al. 2013; Fan, et al. 2012; Szczyrba et al. 2010; Yue, et al. 2012). 232 
However, it remains to be determined how effectively these miRNAs repress VEGF translation 233 
in PCa. Indeed it is also possible that such repression may only occur in specific cellular 234 
contexts. In relation to this latter point, an investigation of the anti7angiogenic effects of 235 
melatonin on hypoxic PCa PC3 cells, determined a melatonin7dependent increase in the 236 
expression of miR7374b. Subsequent studies confirmed miR7374b mediated the anti7angiogenic 237 
effects of melatonin by inhibiting VEGF expression (Sohn, et al. 2015).  238 
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The dissemination of cancer cells from the primary tumor site to distant organs is a key step 241 
during cancer progression. Once cancer cells invade into the bone, liver and lung, no curable 242 
treatment exists. PCa cells preferentially invade into the bone. It is estimated that 70% of 243 
patients with metastatic PCa develop bone metastasis (Semenas, et al. 2012; Shah, et al. 244 
2004). These studies suggest that altered VEGF expression in endothelial cells leads to 245 
impaired blood vessel invasion. As blood vessels serve as a way of transporting circulating 246 
cancer cells, the increased blood vessels beds will increase the transporting of cancer cells into 247 
the blood7vessels enriched organs including liver and lung.   248 
The spread of PCa cells metastasis to bone is a complex process involving local 249 
infiltration of tumour cells into adjacent tissue, migration from the primary tumour site into 250 
vessels (intravasation), survival and dissemination through the vascular system, extravasation, 251 
and finally invasion and subsequent proliferation in bone. There is increasing evidence showing 252 
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that VEGF signaling plays an important role in promoting bone metastasis of PCa. It has been 253 
shown that VEGF signalling initiate metastatic niches to allow cancer cells to home to the bone 254 
marrow during bone metastasis (Kaplan, et al. 2005). VEGF may stimulate the proliferation and 255 
migration of the infiltrated immune cells that secondarily infiltrate tumor tissue to promote PCa 256 
cells to enter into the blood vessels and to disseminate into the distant organs. The expression 257 
of VEGF is also detected in osteoblasts (Maes, et al. 2010).   258 
Previous reported studies have shown that VEGF has autocrine and paracrine effects on 259 
the growth and survival activity of osteoblasts (Dai, et al. 2004; Midy and Plouet 1994; Street, et 260 
al. 2002). Further, bone morphogenesis proteins (BMPs) contribute to PCa–mediated 261 
osteoblastic activity 	
partly through VEGF (Dai et al. 2004). It has also been shown that 262 
VEGF contributes to PCa induced bone remodelling at bone metastatic sites in mouse models 263 
(Kitagawa, et al. 2005) These studies suggest that altered expression of VEGF in both PCa 264 
cells and cells of invaded bone tissue may result in increased activity of bone cells, leading to 265 
an imbalance of bone formation and resorption. VEGF is also functionally linked to adhesion 266 
molecules such as fibronectin and extracellular matrix. These proteins may assist tumour cells 267 
to attract and adhere to the bone microenvironment through VEGF receptors VEGFR1 and 268 
VEGFR2 (Chen, et al. 2004; Sterling, et al. 2011). 269 
VEGF, in addition to its angiogenic role, suppresses the immune system (Figure 3). It 270 
has been shown that VEGF directly or indirectly exerts multiple immunosuppressive activities. It 271 
has been reported that VEGF secreted by mouse tumor cells prevented dendritic cells from 272 
maturing, thus hampering tumor antigen presentation (Gabrilovich, et al. 1996). VEGF 273 
expression is present in cytotoxic T cells and it has been shown that increased expression of 274 
VEGF and VEGFR2 suppressed the activity of T cell receptor CD47 and cytotoxic T cell function 275 
(Kaur, et al. 2014). Altered VEGF signaling may also suppress the function of dendritic cells and 276 
indirectly inhibit T7cell infiltration of tumor tissue. Consistent with this, VEGF blockade has 277 
resulted in increased T7cell homing to tumors and has enhanced the efficacy of immunotherapy 278 
in mouse models (Mellman, et al. 2011).  279 
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The need for a better understanding of the molecular and pathological events involved in PCa 282 
progression has driven the development of animal models. Animal models of PCa can be 283 
distinguished into two broad groups, the first being xenograft of human PCa into immune7284 
compromised mice and the second genetically modified mice (GEM) that will develop prostatic 285 
cancer during their lifetime (Gingrich, et al. 1999; Gray, et al. 2004). Although informative, 286 
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mouse models have several limitations. These include the inability to encompass the full 287 
complexity of the human disease and the inherent resistance to the development of invasive 288 
PCa. Nevertheless, several mouse models have been developed for the study of PCa and these 289 
have been comprehensively reviewed elsewhere (Berman7Booty and Knudsen 2015; 290 
Grabowska, et al. 2014; Wu, et al. 2013). Here we will focus on those that more closely 291 
recapitulate the progression of the human disease (Table 1).  292 
 Several xenograft animal models have been developed to recapitulate progression of 293 
human PCa. The PC3 and LNCaP, derived from an osteolytic and a lymph node metastasis 294 
respectively, are two of the most frequently used cell lines used to study PCa (Kaighn et al., 295 
1979, Horoszewicz, 1980). Several sublines were derived from these original cell lines with 296 
enhanced tumorigenicity  , including LNCaP7Pro375, LNCaP7LN374, PC3M, PC73M7LN4 297 
(Wu et al. 2013). LNCaP7LN3 and LNCaP7Pro5 xenografts are thought to resemble prostatic 298 
adenocarcinomas as xenografts express AR and PSA and are shown to be androgen sensitive 299 
(Pettaway et al., 1996, Yonou et al., 2001). Intravenous or orthotopic injections of LNCaP in 300 
mice are able to metastasize to subcutaneously implanted human adult bone but not murine 301 
bone (Yonou, et al. 2001). Interestingly, one androgen independent subline, LNCaP C472, is 302 
able to metastasize to the bone and cause osteoblastic lesions (Thalmann, et al. 1994). PC3M 303 
xenografts are androgen7insensitive and stain negative for PSA and AR, with the subline PC7304 
3M7LN4 forming bone, lymphatic and lung metastases after orthotopic or intravenous injection 305 
into mice (Pettaway et al., 1996, Yonou et al., 2001). Overall, this data suggests LNCaP 306 
xenografts may model an earlier stage PCa progression than PC3.  307 
The WISH7PC2 xenograft model was derived from a poorly differentiated 308 
adenocarcinoma that was treated with androgen deprivation and histologically consistent with a 309 
neuroendocrine (NE) PCa upon implantation (Pinthus et al., 2000). WISH7PC2 orthotopic 310 
xenografts are able to metastasize to the lymph nodes, lung and liver, and when injected locally 311 
can form tumors within bone and liver tissues (Pinthus et al., 2000). Other NE PCa relevant 312 
models include the LTL352 and LTL370 derived from metastatic NE PCa resected from urethral 313 
and penile areas, respectively. Like WISH7PC2, these xenografts stain negative for PSA and 314 
AR, and can grow in androgen deprived mice with rapid doubling time. A major limitation of 315 
xenograft models is that most tissues are obtained from advanced and aggressive PCas and 316 
therefore tend to model later stages of the disease. Furthermore, one intrinsic limitation of 317 
xenografts is that these systems depend upon effective murine vascularization of human cancer 318 
cell masses and may therefore not fully recapitulate all aspects of tumors in patients. 319 
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Nevertheless, the xenograft models, especially LNCaP xenografts, have been instrumental for 320 
understanding PCa and for many preclinical studies.  321 
 Transgenic mouse models can approximate the different stages of PCa progression, 322 
from low grade to high grade prostate intraepithelial neoplasia (PIN), adenocarcionoma and 323 
metastatic cancer. Early models utilised expression of viral oncogenes (such as small and large 324 
SV40 tumour antigens under the control of the prostate7specific probasin (PB) promoter) in the 325 
prostate epithelium. The viral oncogene models differ from human PCa as they present a rapid 326 
progression of the disease and predominant NE differentiation. However, they have been 327 
recognised as relevant models for PCa, and very useful for the investigation of CRPC that 328 
progresses to NE carcinoma (Berman7Booty and Knudsen 2015). In the TRAMP (transgenic 329 
adenocarcinoma mouse prostate) model a rapid progression of PCa with lymph node and lung 330 
metastasis was observed, with bone metastasis only reported for the FVB mouse background 331 
(Gingrich, et al. 1996). The TRAMP mice also respond to castration and can progress to 332 
hormone refractory disease associated with NE differentiation and increased metastasis rate 333 
(Gingrich, et al. 1997; Kaplan7Lefko, et al. 2003). Similarly some of LADY mouse model lines 334 
(e.g 12T77s7f/PB7hepsin, and 12T10), drive invasive carcinoma and NE carcinoma with 335 
metastasis to the liver, lung and bone (Klezovitch, et al. 2004; Masumori, et al. 2001). The 336 
second generation mouse models were based on human PCa genetic alterations, including loss 337 
of the tumour suppressor genes     and amplification of the  338 
oncogene. Interestingly, none of the single gene deletion models shows a significant PCa 339 
phenotype but their synergistic inactivation results in the cancer onset. For instance, 340 
simultaneous inactivation of p53 and Rb results in the formation of highly metastatic tumors that 341 
are resistant to castration and showing NE differentiation (Zhou, et al. 2006). The best of these 342 
new models incorporate multiple genetic lesions with Cre7gene targeting. The most utilised 343 
models are based on the conditional targeted deletion of PTEN and they seem to recapitulate 344 
the disease progression seen in humans, including the development of CRPC with activation of 345 
PI3K/Akt signalling (Grabowska et al. 2014; Wang, et al. 2003). 346 
 Despite being the main angiogenic factor involved in PCa progression and metastasis, 347 
few studies have examined the role of VEGF in PCa animal models. Xenografts of PCa and 348 
benign prostate primary tissue exhibit maturation of vascularisation at 30 days with the 349 
presence of small vessel of human origin containing red blood cells within (Gray et al. 2004; 350 
Montecinos, et al. 2012; Presnell, et al. 2001). These xenograft tumors exhibit a surge of 351 
angiogenesis at day 6 post7implantation into mice, preceded by an up7regulation of VEGF in the 352 
stromal counterpart of the tumour at day 2 (Montecinos et al. 2012). A further increase in VEGF 353 
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protein is also shown to modulated through the addition of human testosterone pellets implanted 354 
into castrated mice when compared to the controls (Montecinos et al. 2012). This data suggests 355 
a role for VEGF in angiogenesis establishment and PCa progression through androgen 356 
regulation. During androgen deprivation (AD), a marked reduction in microvascular density 357 
(MVD) is seen after 2 days followed by vascular reestablishment from days 7 and 14 (Godoy, et 358 
al. 2011). The expression of VEGF and VEGFR2 increased in epithelial cells 2 days post AD 359 
suggesting a compensatory role for these molecules in survival of PCa and progression (Godoy 360 
et al. 2011). This data suggests androgen7dependent and independent mechanisms for VEGF 361 
induction. As described above, most xenograft models use primary PCa tissue, however PCa 362 
cell lines have been exploited in a subset of studies. For example, PC3 has been used to 363 
investigate the use of drugs to inhibit VEGF signalling (Anai, et al. 2011; Pang, et al. 2011a; 364 
Pang, et al. 2011b). Similarly, the LNCaP7LN3 orthotopic xenograft has been used to evaluate 365 
the response of bone metastasis to the anti7VEGF receptor antibody DC101 (Sweeney, et al. 366 
2002).  367 
The TRAMP model has been used to study angiogenic responses. Pathologically, the 368 
TRAMP mice of the FVB genetic background show highly vascularised tumors with early onset 369 
of angiogenic switch, together with loss of E7cadherin expression indicative of epithelia7to7370 
mesenchymal transition (EMT) (Chiaverotti, et al. 2008; Gingrich et al. 1999; Kaplan7Lefko et al. 371 
2003). Based on histological and immunohistochemical analysis, TRAMP mice tumors also 372 
show high VEGF and FGF72 expression, with increased microvessel density. Importantly, these 373 
mice recapitulate the stimulation of angiogenesis observed in the aged mouse prostate, which is 374 
sensitive to treatment with antiangiogenic drugs (TNP7470 alone or in combination with 375 
SU5416) and finasteride (Montico, et al. 2014). The role of VEGF in advanced PCa has also 376 
been studied in 	 conditional knockout mice. PCa cells in these mice express the VEGF 377 
receptor NRP2 and activate signalling leading to expression of the Polycomb transcriptional 378 
repressor Bmi71, which is implicated in the onset of PCa induced by Pten deletion (Goel, et al. 379 
2012). This highlights an important role of VEGF/NRP2 signalling in PCa and the need to 380 
develop new therapies specifically targeting of this pathway (Geretti, et al. 2010).  381 
 382 
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High tumor VEGF levels have been associated with poor treatment outcome in PCa and 384 
higher VEGF serum levels has been described in patients with metastatic disease than in those 385 
with localized disease (Duque et al. 1999; Green et al. 2007). The use of anti7VEGF therapies in 386 
preclinical and clinical studies has been associated with increased side effects including 387 
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hypertension, gastrointestinal bleeding, intestinal perforation and pulmonary embolism 388 
(Mangoni, et al. 2012; Ogita, et al. 2012). Although bevacizumab has shown some promise with 389 
improved progression free survival, no significant improvement in overall survival has been 390 
achieved even in combination therapies (reviewed in Armstrong, et al. 2013; Small and Oh 391 
2012). A newer anti7angiogenesis agent derived from the extra7cellular domains of the VEGFR 392 
(aflibercept) in combination with docetaxel and prednisone also offered no improvement in 393 
overall survival (Tannock, et al. 2013). Yet given the comparative success of trials of newer 394 
agents targeting VEGF signalling in other cancer types (Grothey, et al. 2013; Qi, et al. 2011), 395 
further studies are required of these agents in the PCa setting. Indeed Cediranib, a VEGFR 396 
receptor tyrosine kinase inhibitor was tested in a phase II trial on docetaxel pre7treated CRPC 397 
patients as monotherapy and was found to be well tolerated with some anti7tumour activity 398 
(Dahut, et al. 2013). There are ongoing phase II trial using Cediranib in combination with 399 
docetaxel plus prednisone or with abiraterone (ClinicalTrials.gov identifier NCT00527124 and 400 
NCT01574937 respectively) in hormone refractory PCa. A phase I trial combining abiraterone 401 
with cabozantinib is also ongoing (NCT01574937) likewise a phase II trial combining 402 
bevacizumab, lenalidomide, docetaxel, and prednisone (ART7P) for treatment of metastatic 403 
castrate7resistant PCa (NCT00942578). Given the immuno7suppressive and pro7angiogenic 404 
actions of VEGF new combinations therapies targeting VEGF signalling and promoting immune 405 
function are likely to emerge (reviewed in Cheng and Fong 2014). However further studies are 406 
required to not only identify the optimal therapeutic combinations, but also the sequencing of 407 
therapies with respect to cytotoxic chemotherapy use. This is of particular significance given 408 
that reduced tumor angiogenesis achieved by anti7VEGF therapies may impair optimal delivery 409 
of chemotherapeutics within tumor masses (Carmeliet and Jain 2011).  410 
 411 
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Radiation therapy is an important treatment modality for the management of 413 
malignancies. Preclinical studies have demonstrated that in addition to inducing cell death, 414 
radiation also damages tumor vasculature and prevents tumor angiogenesis (El Kaffas, et al. 415 
2013). However local treatment failures occur in many patients after initial response to radiation 416 
therapy. Such recurrent diseases are noted to be more aggressive, resistant to therapy and 417 
have poor prognosis (Punnen, et al. 2013). Recurrence has been partly attributed to subsequent 418 
improvements in the tumour vasculature induced by radiation treatment. It has been reported 419 
that following radiation therapy, pro7angiogenic factors including VEGF are induced in remaining 420 
malignant and stromal cells in the tumour. Mobilization of pro7angiogenic CD11b positive 421 
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myelomonocytic cells from the bone marrow to the tumour stroma has also been noted to 422 
improve the revascularization of the tumor bed (Martin 2013 and references therein). Thus anti7423 
VEGFs such as bevacizumab may both sensitize the tumor to radiotherapy and block post7424 
therapy re7vascularization (Zhuang, et al. 2014). However the combination of radiation therapy 425 
with anti VEGF therapies in PCa has not been extensively studied clinically. A phase II study 426 
reported by Vuky and colleagues (2012) examined long7term androgen suppression with 427 
bevacizumab and intensity7modulated radiation therapy (IMRT) in high7risk PCa with acute and 428 
late toxicity as end points. It was reported that the addition of bevacizumab did not appear to 429 
worsen the effect of radiotherapy in PCa. A phase I trial which has recently completed 430 
recruitment is also studying the toxicity associated with the combination of sunitinib with 431 
hormone ablation and radiotherapy in patients with PCa (ClinicalTrials.gov. identifier 432 
NCT00631529). More trials with overall survival as endpoint are needed to assess the effect of 433 
combining anti VEGFs with radiation therapy in prostate CRPC. 434 
 435 
$	
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436 
Tumors must exploit pro7angiogenesis pathways to metastasize. For this reason targeting 437 
VEGF signalling remains an attractive approach to prevent, delay or reverse tumor metastasis. 438 
The clinical utility of anti7angiogenesis therapy for metastatic PCa has been disappointing to 439 
date. Such therapies have almost exclusively targeted circulating VEGF or the tyrosine kinase 440 
activity of VEGF receptors. However recent advances in understanding of the regulation of 441 
 in prostate cells (Kashyap et al. 2013) raises the potential to pharmacologically target 442 
epigenetic complexes involved in the hormonal regulation of  expression. Indeed with the 443 
approval of the HDAC inhibitors, vorinostat(SAHA) and romidepsin, for the treatment of 444 
cutaneous T7cell lymphoma and with trials of epigenetic targeted therapies for PCa ongoing 445 
(Campbell and Tummino 2014), the simultaneous targeting of pro7androgenic, pro7estrogenic 446 
and pro7angiogenic pathways with small molecular inhibitors of nuclear receptor coregulators is 447 
an increasingly attractive approach.    448 
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